The EGF+61 polymorphism (AG and AG + GG) was associated with stable disease in both univariate and multivariate in NSCLC patients treated with first‐generation TKIs harboring EGFR‐sensitizing mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.